These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22592550)

  • 1. Heterologous expression of the C-terminal antigenic domain of the malaria vaccine candidate Pfs48/45 in the green algae Chlamydomonas reinhardtii.
    Jones CS; Luong T; Hannon M; Tran M; Gregory JA; Shen Z; Briggs SP; Mayfield SP
    Appl Microbiol Biotechnol; 2013 Mar; 97(5):1987-95. PubMed ID: 22592550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmodium falciparum: heterologous synthesis of the transmission-blocking vaccine candidate Pfs48/45 in recombinant vaccinia virus-infected cells.
    Milek RL; DeVries AA; Roeffen WF; Stunnenberg H; Rottier PJ; Konings RN
    Exp Parasitol; 1998 Oct; 90(2):165-74. PubMed ID: 9769246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steps toward a globally available malaria vaccine: harnessing the potential of algae for future low cost vaccines.
    Jones CS; Mayfield SP
    Bioengineered; 2013; 4(3):164-7. PubMed ID: 23090388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based
    Singh SK; Plieskatt J; Chourasia BK; Fabra-García A; Garcia-Senosiain A; Singh V; Bengtsson KL; Reimer JM; Sauerwein R; Jore MM; Theisen M
    Front Immunol; 2020; 11():606266. PubMed ID: 33505395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering the chloroplast of Chlamydomonas reinhardtii to express the recombinant PfCelTOS-Il2 antigen-adjuvant fusion protein.
    Shamriz S; Ofoghi H
    J Biotechnol; 2018 Jan; 266():111-117. PubMed ID: 29269249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malaria vaccine.
    Khurana SK; Talib VH
    Indian J Pathol Microbiol; 1996 Dec; 39(5):433-41. PubMed ID: 9002371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat-precipitation allows the efficient purification of a functional plant-derived malaria transmission-blocking vaccine candidate fusion protein.
    Beiss V; Spiegel H; Boes A; Kapelski S; Scheuermayer M; Edgue G; Sack M; Fendel R; Reimann A; Schillberg S; Pradel G; Fischer R
    Biotechnol Bioeng; 2015 Jul; 112(7):1297-305. PubMed ID: 25615702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine.
    Theisen M; Jore MM; Sauerwein R
    Expert Rev Vaccines; 2017 Apr; 16(4):329-336. PubMed ID: 28043178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Algae-produced Pfs25 elicits antibodies that inhibit malaria transmission.
    Gregory JA; Li F; Tomosada LM; Cox CJ; Topol AB; Vinetz JM; Mayfield S
    PLoS One; 2012; 7(5):e37179. PubMed ID: 22615931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1.
    Rodrigues MH; Rodrigues KM; Oliveira TR; Cômodo AN; Rodrigues MM; Kocken CH; Thomas AW; Soares IS
    Int J Parasitol; 2005 Feb; 35(2):185-92. PubMed ID: 15710439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a Plasmodium berghei sexual stage antigen PbPH as a new candidate for malaria transmission-blocking vaccine.
    Kou X; Zheng W; Du F; Liu F; Wang M; Fan Q; Cui L; Luo E; Cao Y
    Parasit Vectors; 2016 Apr; 9():190. PubMed ID: 27038925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation.
    Datta D; Bansal GP; Gerloff DL; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2017 Jan; 35(2):264-272. PubMed ID: 27912985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An efficient approach to the production of vaccines against the malaria parasite.
    Tsuboi T; Takeo S; Sawasaki T; Torii M; Endo Y
    Methods Mol Biol; 2010; 607():73-83. PubMed ID: 20204850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geographical distribution of a variant epitope of Pfs48/45, a Plasmodium falciparum transmission-blocking vaccine candidate.
    Drakeley CJ; Duraisingh MT; Póvoa M; Conway DJ; Targett GA; Baker DA
    Mol Biochem Parasitol; 1996 Oct; 81(2):253-7. PubMed ID: 8898341
    [No Abstract]   [Full Text] [Related]  

  • 17.
    Singh SK; Thrane S; Chourasia BK; Teelen K; Graumans W; Stoter R; van Gemert GJ; van de Vegte-Bolmer MG; Nielsen MA; Salanti A; Sander AF; Sauerwein RW; Jore MM; Theisen M
    Front Immunol; 2019; 10():1256. PubMed ID: 31231386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages.
    Theisen M; Roeffen W; Singh SK; Andersen G; Amoah L; van de Vegte-Bolmer M; Arens T; Tiendrebeogo RW; Jones S; Bousema T; Adu B; Dziegiel MH; Christiansen M; Sauerwein R
    Vaccine; 2014 May; 32(22):2623-30. PubMed ID: 24662702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of cross-protective antibodies against Plasmodium falciparum sequestration by immunization with an erythrocyte membrane protein 1-duffy binding-like 1 alpha domain.
    Moll K; Pettersson F; Vogt AM; Jonsson C; Rasti N; Ahuja S; Spångberg M; Mercereau-Puijalon O; Arnot DE; Wahlgren M; Chen Q
    Infect Immun; 2007 Jan; 75(1):211-9. PubMed ID: 17074852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of Plasmodium yoelii merozoite surface protein 4/5 produced in transgenic plants.
    Wang L; Webster DE; Campbell AE; Dry IB; Wesselingh SL; Coppel RL
    Int J Parasitol; 2008 Jan; 38(1):103-10. PubMed ID: 17681344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.